scholarly journals In Vitro Activity of Vancapticin MCC5145 against Methicillin-Resistant Staphylococcus aureus from Periprosthetic Joint Infection

2021 ◽  
Author(s):  
Hye-Kyung Cho ◽  
Melissa J. Karau ◽  
Kerryl E. Greenwood-Quaintance ◽  
Karl A. Hansford ◽  
Matthew A. Cooper ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Periprosthetic Joint Infection ◽  
Biofilm Formation ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Joint Infection ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Methicillin Resistant

MRSA periprosthetic 1 joint infection (PJI) can be challenging to treat due to biofilm formation, alongside sometimes limited vancomycin activity (1-3).…

scholarly journals 1255. In Vitro Activity of Vancapticin against Methicillin-Resistant Staphylococcus aureus from Periprosthetic Joint Infection

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S645-S645
Author(s):  
Hye-Kyung Cho ◽  
Melissa J Karau ◽  
Kerryl E Greenwood-Quaintance ◽  
Karl A Hansford ◽  
Matthew A Cooper ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Periprosthetic Joint Infection ◽  
Mayo Clinic ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Joint Infection ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Research Support ◽  
Material Support

Abstract Background The vancapticins are modified vancomycin derivatives developed by adding membrane targeting motifs to the C-terminus of vancomycin. We determined the in vitro activity of a lead vancapticin candidate against periprosthetic joint infection-associated methicillin-resistant Staphylococcus aureus (MRSA) in the planktonic and biofilm states, and the effect of adding 0.002% polysorbate 80 (P-80; Sigma-Aldrich) on vancapticin susceptibility testing. Methods Thirty-seven clinical isolates of MRSA collected at Mayo Clinic (Rochester, Minnesota) were studied. Vancapticin minimum inhibitory concentrations (MICs) were determined using Clinical and Laboratory Standards Institutes guidelines. Minimum biofilm bactericidal concentrations (MBBCs) were determined using a pegged lid microtiter plate assay. Vancapticin MIC and MBBC values were assessed with and without P-80. Vancapticin, vancomycin, and dalbavancin biofilm time-kill assays were performed using biofilms formed by 10 MRSA isolates on Teflon coupons. Results Vancapticin MICs with and without P-80 ranged from 0.015 to 0.12 μg/mL and 0.25 to 1 μg/mL, respectively. Vancapticin MBBCs with and without P-80 ranged from 0.25 to 4 μg/mL and 1 to 8 μg/mL, respectively. Reductions of biofilm bacterial densities on Teflon coupons after 8 and 24 hours of incubation with vancapticin, vancapticin with P-80, vancomycin, or dalbavancin with P-80 were less than 3-log10 cfu/cm2 for all isolates tested. Conclusion Vancapticin has promising in vitro activity against planktonic MRSA and MRSA in a pegged lid biofilm assay, but was not bactericidal against biofilms on Teflon coupons. P-80 decreased vancapticin MICs and MBBCs. Disclosures Mark A. Blaskovich, PhD, MAB Consulting (Consultant)The University of Queensland (Employee, Grant/Research Support, Other Financial or Material Support, Inventor on patent) Robin Patel, MD, Accelerate Diagnostics (Grant/Research Support)CD Diagnostics (Grant/Research Support)Contrafect (Grant/Research Support)Curetis (Consultant)GenMark Diagnostics (Consultant)Heraeus Medical (Consultant)Hutchison Biofilm Medical Solutions (Grant/Research Support)Merck (Grant/Research Support)Next Gen Diagnostics (Consultant)PathoQuest (Consultant)Qvella (Consultant)Samsung (Other Financial or Material Support, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued.)Selux Dx (Consultant)Shionogi (Grant/Research Support)Specific Technologies (Consultant)

scholarly journals In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus

2011 ◽  
Vol 64 (8) ◽  
pp. 559-562 ◽  
Author(s):  
Chunguang Sun ◽  
Matthew E Falagas ◽  
Rui Wang ◽  
Drosos E Karageorgopoulos ◽  
Xuhong Yu ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Methicillin Resistant

scholarly journals In Vitro 24-Hour Time-Kill Studies of Vancomycin and Linezolid in Combination versus Methicillin-Resistant Staphylococcus aureus

2009 ◽  
Vol 53 (10) ◽  
pp. 4495-4497 ◽  
Author(s):  
Shveta Rani Singh ◽  
Alfred E. Bacon ◽  
David C. Young ◽  
Kimberly A. Couch
Keyword(s):  
Staphylococcus Aureus ◽  
Conventional Therapy ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Antagonistic Activity ◽  
Vitro Activity ◽  
Synergistic Activity ◽  
In Vitro Activity ◽  
Methicillin Resistant ◽  
Time Kill

ABSTRACT Many clinicians are trying unique strategies, including vancomycin and linezolid in combination, for treatment of patients who do not respond to conventional therapy against methicillin (meticillin)-resistant Staphylococcus aureus. In our study, which illustrated in vitro activity only, no synergistic activity was seen when the two agents were combined. Conversely, antagonistic activity occurred in three of five strains when linezolid was added to vancomycin. Our results indicate that vancomycin and linezolid in combination should be avoided.

Sign in / Sign up

Export Citation Format

Share Document